Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof

• US 20060084704A1
• Filed: 09/02/2005
• Published: 04/20/2006
• Est. Priority Date: 01/28/2004
• Status: Abandoned Application

• Current Assignee: AndroScience Corporation
• Original Assignee: AndroScience Corporation
• Inventors: Su, Ching-Yuan, Shih, Charles
• Application Number:
  US11/218,889
• Publication Number:
  US 20060084704A1
• Time in Patent Office: Days
• US Class Current: 514/688
• CPC Class Codes: A61K 31/12 Ketones
• CPC Class Codes: A61K 8/35 Ketones, e.g. benzophenone
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61Q 19/00 Preparations for care of the skin

Abstract

The present invention includes methods, compositions, cosmetics and pharmaceutical compositions for enhancing the degradation of a nuclear receptor (NR) or a STAT transcription factor protein. The methods, compositions, cosmetics and pharmaceuticals may be used to prevent or treat disorders or medical conditions that are at least in part affected by a nuclear receptor activation pathway or STAT activation pathway.

Claims

1. A method of inhibiting a nuclear receptor activation pathway, comprising:

a) providing a cell comprising a nuclear receptor activation pathway; and

b) introducing a compound capable of enhancing degradation of a nuclear receptor in said nuclear receptor activation pathway.

2. The method according to claim 1, wherein said cell is a mammalian cell.

3. The method according to claim 1, wherein said cell is a human cell or a cell derived from a human cell.

4. The method according to claim 1, wherein said nuclear receptor activation pathway comprises a STAT signalling pathway.

5. The method according to claim 1, wherein said nuclear receptor activation pathway is an androgen receptor (AR) pathway or a progesterone receptor (PR) pathway.

6. The method according to claim 1, wherein said nuclear receptor activation pathway is selected from the group consisting of an estrogen receptor (ER) pathway, a glucocorticoid receptor (GR) pathway, a 9-cis retenoic acid (RXR) pathway and a trans-retenoic acid (RAR) pathway.

7. The method according to claim 1, wherein said compound is a curcumin analogue or a curcumin derivative.

8. The method according to claim 7, wherein said curcumin analogue or said curcumin derivative is JC9 or JC15.

9. The method according to claim 7, wherein said curcumin analogue or said curcumin derivative is an analogue or derivative of JC9 or JC15.

10. The method according to claim 1, wherein said compound enhances degradation of said nuclear receptor by a method selected from the group consisting of interfering with phosphorylation of said nuclear receptor, interfering with dimerization of said nuclear receptor, interfering with binding of said nuclear receptor to a cofactor, and interfering with nuclear translocation of said nuclear receptor.

11. A method of inhibiting a STAT activation pathway comprising:

a) providing a cell comprising a STAT activation pathway; and

b) introducing a compound capable of enhancing degradation of a STAT transcription factor protein in said nuclear receptor activation pathway.

12. The method according to claim 11, wherein said STAT transcription factor protein is selected from the group consisting of:

STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6.

13. The method according to claim 11, wherein said compound inhibits or reduces an immune response.

14. A cosmetic composition comprising:

a) a compound capable of inducing degradation of a nuclear receptor; and

a) a cosmetically acceptable carrier.

17. The cosmetic according to claim 14, wherein said cosmetic is for the prevention or treatment of a skin disorder.

18. The cosmetic according to claim 14, wherein said cosmetic is for the prevention or treatment of a medical condition selected from the group consisting of inflammation, acne, baldness, hirsutism, an exposed wound, a burn, atopic dermatitis, enzema, psoriasis.

15. The cosmetic composition according to claim 15, wherein said compound is a curcumin analogue or curcumin derivative.

16. The cosmetic according to claim 15, wherein said compound is JC9 or JC15.

19. A cosmetic composition comprising:

a) a compound capable of inducing degradation of a STAT transcription factor protein; and

b) a cosmetically acceptable carrier.

20. The cosmetic composition according to claim 19, wherein said cosmetic is treats or prevents a skin disorder selected from the group consisting of inflammation, acne, atopic dermatitis, enzema and psoriasis.

21. A pharmaceutical composition comprising:

a) a compound or a pharmaceutically acceptable salt thereof capable of enhancing degradation of a nuclear receptor; and

b) a pharmaceutically acceptable carrier.

22. The pharmaceutical composition according to claim 21, wherein said compound is a curcumin derivative or analogue.

23. The pharmaceutical composition according to claim 21, wherein said nuclear receptor is a steroid hormone receptor.

24. The pharmaceutical composition according to claim 23, wherein said steroid hormone receptor is selected from the group consisting of the androgen receptor (AR), the progesterone receptor (PR), the estrogen receptor α

(ER α

) and the estrogen receptor β

(ER β

).

25. The pharmaceutical composition according to claim 21, wherein said pharmaceutical is for the prevention or treatment of a medical condition selected from the group consisting of male infertility, Kennedy disease, prostate cancer, breast cancer, liver cancer, bladder cancer, benign prostate hyperplasia, acne, baldness, hirsutism, an exposed wound, and a diabetic ulcer.

26. The pharmaceutical composition according to claim 21, wherein said pharmaceutical composition is useful in preventing conception in females of child-bearing age.

27. The pharmaceutical composition according to claim 21, wherein said pharmaceutical is used as a veterinary contraceptive or for a veterinary still birth procedure.

28. The pharmaceutical composition according to claim 21, wherein said pharmaceutical composition inhibits or reduces an immune response.

29. A method to prevent or treat a cause or symptom of a medical condition that is, at least in part, affected by the activity of a nuclear receptor, comprising administering the pharmaceutical composition of claim 21 to an individual suffering from a cause or symptom or medical condition that is at least in part, affected by the activity of a nuclear receptor.

30. The method of claim 29, wherein said nuclear receptor is a steroid hormone receptor and said medical condition is selected from the group consisting of male infertility, Kennedy disease, prostate cancer, breast cancer, liver cancer, bladder cancer, benign prostate hyperplasia, acne, baldness, hirsutism, slow wound healing, and unwanted pregnancy.